1.Finelli, L, Miller, JT, Tokars, JI, Alter, MJ, Ardunio, MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005;18:52–61.
2.Simmonds, P, Holmes, EC, Cha, TA, et al.Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391–2399.
3.Tugwell, BD, Patel, PR, Williams, IT, et al.Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor. Ann Intern Med 2005;143:648–655.
4.Henderson, DK. Managing occupational risks for hepatitis C transmission in the health care setting, 2003. Clin Microbiol Rev 2003;16:546–568.
5.Centers for Disease Control and Prevention (CDC). Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001;50(RR-5):1–43.
6.CDC. Transmission of hepatitis B and C viruses in outpatient settings: New York, Oklahoma, and Nebraska, 2000-2002. MMWR Morb Mortal Wkly Rep 2003;52:901–906.
7.Krause, G, Trepka, MJ, Whisenhunt, RS, et al.Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. Infect Control Hosp Epidemiol 2003;24:122–127.
8.Alter, MJ. Healthcare should not be a vehicle for transmission of hepatitis C virus. J Hepatol 2008;48:2–4.
9.CDC. Infection control requirements for dialysis facilities and clarification regarding guidance on parenteral medication vials. MMWR Morb Mortal Wkly Rep 2008;57:875–876.
10.Siegel, JD, Rhinehart, E, Jackson, M, Chiarello, L, the Healthcare Infection Control Practices Advisory Committee, 2007. Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings, June 2007. Available at: http://www.cdc.gov/ncidod/dhqp/gl_isolation.html. Accessed December 31, 2008.